Editas Medicine Inc
NASDAQ:EDIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zhejiang Lante Optics Co Ltd
SSE:688127
|
CN |
|
N
|
Nan Yang Dyeing & Finishing Co Ltd
TWSE:1410
|
TW |
|
Creek & River Co Ltd
TSE:4763
|
JP |
|
Naigai Tec Corp
TSE:3374
|
JP |
|
A
|
Archicom SA
WSE:ARH
|
PL |
|
T
|
Teekay Tankers Ltd
NYSE:TNK
|
CA |
|
Nippon Pallet Pool Co Ltd
TSE:4690
|
JP |
Editas Medicine Inc
Total Receivables
Editas Medicine Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Total Receivables
$15.2m
|
CAGR 3-Years
44%
|
CAGR 5-Years
20%
|
CAGR 10-Years
31%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$12.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$9.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$2.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
See Also
What is Editas Medicine Inc's Total Receivables?
Total Receivables
15.2m
USD
Based on the financial report for Dec 31, 2025, Editas Medicine Inc's Total Receivables amounts to 15.2m USD.
What is Editas Medicine Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
31%
Over the last year, the Total Receivables growth was -7%. The average annual Total Receivables growth rates for Editas Medicine Inc have been 44% over the past three years , 20% over the past five years , and 31% over the past ten years .
